|
 
- 积分
- 429
- 威望
- 429
- 包包
- 1768
|
本帖最后由 qianqianlaile 于 2011-3-21 11:29 编辑 ( D7 u% m# ?, w6 s
+ J$ V* M* s5 p7 G3 P; c1 j. vINTRODUCTION+ W) X: ]; p; v
Cell therapy has tremendous potential in regenerative medicine, yet, there are concerns in
' L, G7 Q3 {6 I9 |the utility of cell therapy due to questions regarding different cell harvest and cultivation + r8 e! D0 \! A
methods (Haack-Sorensen et al., 2008; Mannello and Tonti, 2007). Bone marrow derived
' v/ }. ^; q0 ^0 K( h; `0 D5 bstem cells have been identified for a number of years, and there are a number of
0 a y: }" |' k6 Y1 s5 |ongoing clinical trials exploring the safety and efficacy of their use for a number of . q0 g+ Z( I7 t, ?; C
clinical applications (Battiwalla and Hematti, 2009; Sadan et al., 2009; Satija et al.,
$ [! X! t( ~( r: e+ k2009). There has been an increased interest in recent years in the potential of oral-. i; N( V0 d+ b/ F- k% `
derived stem cells for cell therapy, primarily because they can be derived from a readily
& b; o! k0 e, y! `3 S3 Eavailable source, extracted teeth (Gronthos et al., 2000; Miura et al., 2003; Seo et al.,
% y# ^. I1 w' r8 B" F) ?4 \9 S+ z* e' I2004). These cells exhibit multipotency and regenerative capacities characteristic of
& n! T0 k: {, _0 M1 \$ @- R; hmesenchymal stem cells (Batouli et al., 2003; Shi et al., 2005) and have the capacity to 1 }0 _3 `) u3 ^, R
repair and regenerate tooth structures in vivo (Krebsbach and Robey, 2002; Mao et al., 2006). ' H5 d# H; q9 N. n4 D: o p5 ?
Because oral-derived stem cells have been more recently identified, clinical
; V$ _4 ?8 [7 p9 G( K v5 H& W7 Vprotocols are still being developed for their use. Regardless of the specific protocol
8 R7 z, S/ }% H v. P( lused, most current cell therapy approaches rely upon ex vivo cell expansion in order to ( W2 t" K1 Z: q; D* O4 v7 c
produce sufficient cell numbers for transplantation. Though a wide variety of protocols / F+ ]/ |* ~3 Y
and culturing methods exist, one common aspect to most of them is the inclusion of / z; b: P; L4 I# _/ n. s, a( l) `
animal sera for cell expansion, in that it contains a rich source of nutrients and growth " ]- Y% _1 c6 C9 }0 y6 V
factors (Mannello and Tonti, 2007). Despite the widespread standard use of animal
% }0 f w* E" H6 Z) X8 Bsera for in vitro cell culture (Freshney, 2000), there are several problems which exist 5 W8 L( q* O) S( H A" e
relative to its use for clinical application.
: ]6 d: i" r% [2 p6 f" a" AOne of the central issues regarding limitations in using animal sera for clinical cell
1 g7 p! f9 D6 btherapy protocols is that its components are highly variable and, in many cases,
$ p2 Z- O+ o5 C, p/ Gunknown. Though components of sera have identified, it has also been demonstrated ' ~) m, i o0 M$ j
that consistency between different lots cannot be assured (Price and Gregory, 1982). In
; O! U1 _- O5 u: _, Nthe context of multipotent stem cells, serum components and concentrations have 3 J* P" N- G. i/ Z4 k
significant impact on cell survival and proliferative capacity, phenotype, and multipotent
& Q- G1 B: }/ q* h- xpotential (Agata et al., 2009; Sotiropoulou et al., 2006). Additionally, for clinical use, the
( ^# q& N5 ~, G: d; H ^4 T8 finclusion of xenogeneic serum for cell expansion carries immunological risks associated
6 m+ }% L; ` x2 e8 s3 lwith the immunogenicity of serum proteins and the potential of transmission of prion
; a6 M" M* d, }0 U" x' F# T$ udiseases and zoonoses (Shahdadfar et al., 2005). These concerns have led to efforts $ w6 W# e) }1 k- j2 Y1 d
aimed at incorporating FBS alternatives in cell expansion protocols, including the use of ( I3 L) a/ u) Y2 W5 H5 e
autologous and allogeneic sera, and the proprietary manufacturing of serum-free media + s4 t% c* h) S
formulations by different companies (Nakamura et al., 2008). Even with these approaches,8 m% c3 l: K( N9 }
there are limitations in the availability of both autologous and allogeneic
8 R# x( _5 \3 l# y- m6 z, Hsera and companies do not freely disclose their proprietary “serum-free” media
( S2 d, a! S4 q- F( lcomponents. These factors not only prohibit clinical translation, but also limit
+ p# g. j$ @) }5 Y) b/ }widespread use and study of more basic fundamental questions regarding specific 2 u/ }8 b" V* z( `( O
mechanisms involved in the modulation of these media on cell function. As such, there " n7 r" R1 k4 W! S8 c; W
exists a need for the development of chemically-defined media which can propagate the
. F2 x9 {# ?( Ecultivation of stem cells without adversely affecting cell function and phenotype
! R7 X5 o: a# l+ d* N7 J7 A(Mannello and Tonti, 2007).3 M9 c) y4 P" r7 n( r: W4 N: m. ?
In this study, we aimed to develop a serum-free media (K-M) for the expansion o6 k+ I2 w6 b; M x4 a, a* d3 L
dental-derived stem cells, including stem cells-derived from exfoliated deciduous (baby)
# |* ~7 G( l [ [0 Tteeth (SHEDs) and periodontal ligament stems cells (PDLSCs). Cell expansion in this
- C" f6 d4 b# C" Q& q& b# J- `media was compared to standard FBS containing media used to culture these cells, 1 L4 I3 `5 n5 ^
as well as three other serum-free media formulations (two of which are commercially available)
. a( Q3 Z4 w# D7 X4 U) U4 C- b/ p: uused for culture of mesenchymal stem cells. Additionally, through ) b8 r) e- n9 i$ u
differentiation assays and microarray analyses, multipotency and differential gene
' H( I+ H/ B6 Eexpression of 84 stem cell associated genes was examined between cells cultured in K-
5 R( A3 [' q" k# @M vs. those cultured in FBS- containing media. |
|
发表于 2011-3-20 08:21
，脑子里也没有独家生产这个概念
，所以没理解。